Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Proqr Therapeutics (NQ: PRQR )

3.770 +0.200 (+5.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Proqr Therapeutics

< Previous 1 2 3 4 Next >
41 Stocks Moving In Friday's Mid-Day Session
Gainers Modular Medical, Inc. (NASDAQ: MODD) shares climbed 34.5% to $4.99 following its recent uplisting to the Nasdaq Capital Market on Thursday. Kaival Brands Innovations... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher As Dow Rises Over 100 Points
U.S. stocks opened on a strong note on Friday, after recording sharp losses in the previous session. 
Via Benzinga
The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adcom Rules That Lilly May Have To Conduct Additional Studies For Co-... 
Via Benzinga
ProQR Shares Crater After Disappointing Sepofarsen Data In Inherited Vision Loss Disorder
ProQR Therapeutics N.V. (NASDAQ: PRQR) shares are plunging after disappointing data from its pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Rise and shine, trader! We're starting off another day of investing with a breakdown of the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
16 Stocks Moving in Tuesday's Pre-Market Session
Gainers ObsEva SA (NASDAQ: OBSV) rose 22.2% to $1.87 in pre-market trading after the company announced a corporate update, including an increase in share capital on... 
Via Benzinga
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia... 
Via Benzinga
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
Exposures Product Safety
Here's Why ProQR Stock Surged on Thursday
A new collaboration deal with Eli Lilly could be worth up to $1.3 billion. 
Via The Motley Fool
Why ProQR Therapeutics's Stock Is Trading Higher Today
ProQR Therapeutics's (NASDAQ:PRQR) shares are trading higher after the company announced Axiomer RNA editing licensing and research collaboration with Lilly. ProQR... 
Via Benzinga
48 Biggest Movers From Yesterday
Gainers Rocket Lab USA, Inc. (NASDAQ: RKLB) jumped 37.3% to settle at $20.72. Rocket Lab reported 1H sales of $29.5 million and announced it has been awarded a contract to deploy... 
Via Benzinga
35 Stocks Moving In Thursday's Mid-Day Session
Gainers Gevo, Inc. (NASDAQ: GEVO) shares climbed 36.6% to $7.91. Chevron and Gevo announced intent to pursue sustainable aviation fuel investment. Offerpad Solutions Inc (NYSE:... 
Via Benzinga
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
Exposures COVID-19
Eli Lilly Inks Another RNA Collab, This Time With ProQR
Eli Lilly And Co (NYSE: LLY) is doubling down on RNA research as it pens another pact with a quiet RNA editing player focused on neuroscience, ProQR... 
Via Benzinga
21 Stocks Moving in Thursday's Pre-Market Session
Gainers Cardiff Oncology, Inc. (NASDAQ: CRDF) rose 17.3% to $8.27 in pre-market trading after the company announced new data from its Phase 1b/2 trial in KRAS-mutated metastatic... 
Via Benzinga
ProQR Therapeutics Stock Is Trading Higher On Antisense Oligonucleotide Development Pact
Yarrow Biotechnology Inc, a newly created company by RTW Investments LP, has in-licensed exclusive rights to ProQR Therapeutics N.V.'s (NASDAQ: ... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers BioLine Rx (NASDAQ:BLRX) shares moved upwards by 65.2% to $5.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $226.7... 
Via Benzinga
An End to This Rare Syndrome Could Be an Opportunity for Investors
A rare genetic disease that causes combined blindness and deafness may have a novel treatment in line after positive phase 1/2 trial results last month. 
Via The Motley Fool
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.